PI3K/AKT and MEK/ERK pathways targeted in new therapy for docetaxel-resistant prostate cancer

  • Post author:
  • Post category:uncategorized

A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d’Oncologia (ICO) and the Germans Trias i Pujol Research Institute (IGTP) have found a new therapeutic strategy for patients with a specific subtype of metastatic prostate cancer resistant to standard chemotherapy treatment with docetaxel.